CEL-SCI Corporation, a clinical stage cancer immunotherapy company, announced the pricing of a $5.7 million offering of its common stock, conducted at-the-market under NYSE American rules. The offering involves 1,500,000 shares priced at $3.82 each. The anticipated gross proceeds, prior to deduction of fees and expenses, total approximately $5.7 million. The closing date for the offering is expected to be July 14, 2025, contingent on customary conditions. Proceeds from the offering will support the continued development of Multikine, as well as general corporate purposes and working capital. ThinkEquity serves as the sole placement agent for the transaction.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。